Dr. Olney is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5050 NE Hoyt St
Ste 315
Portland, OR 97213Phone+1 503-215-8580
Summary
- Nicholas Olney, MD is a neurologist based in Portland, OR, with a clinical focus on neurodegenerative diseases. He completed his neurology residency at UCLA David Geffen School of Medicine/UCLA Medical Center between 2012 and 2015, following a residency in internal medicine at Alameda Health System-Highland Hospital. He graduated from the University of California San Francisco School of Medicine in 2011. He has contributed significantly to medical literature with numerous publications in reputable journals like The Lancet Neurology, Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, Neurodegenerative Disease Management, JAMA Neurology, and Alzheimer's & Dementia. His publications have been cited multiple times by other scholarly articles, indicating their relevance in the field of neurology.
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Neurology, 2012 - 2015
- Alameda Health System-Highland HospitalResidency, Internal Medicine, 2011 - 2012
- University of California San Francisco School of MedicineClass of 2011
Certifications & Licensure
- CA State Medical License 2012 - Present
- OR State Medical License 2018 - 2025
- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial.Steven Perrin, Shafeeq Ladha, Nicholas Maragakis, Michael H Rivner, Jonathan Katz
Plos Medicine. 2024-10-01 - Real world experience with sodium phenylbutyrate-taurursodiol for ALS: Lessons learned from a failed drug.Nicholas Olney, Michael D Weiss
Muscle & Nerve. 2024-09-01 - 4 citationsSafety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, pha...Michael Benatar, Thomas Hansen, Dror Rom, Marie A Geist, Thomas Blaettler
The Lancet. Neurology. 2024-07-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: